Cargando…
Advances in CXCR7 Modulators
CXC chemokine receptor 7 (CXCR7) is a G-protein-coupled receptor that signals through the β-arrestin pathway. Its ligands include interferon-inducible T cell α chemoattractant (CXCL11) and stromal cell-derived factor-1 (CXCL12). It interacts with CXCR4, and the two are associated with various cancer...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169404/ https://www.ncbi.nlm.nih.gov/pubmed/32098047 http://dx.doi.org/10.3390/ph13020033 |
_version_ | 1783523782613270528 |
---|---|
author | Lounsbury, Nicole |
author_facet | Lounsbury, Nicole |
author_sort | Lounsbury, Nicole |
collection | PubMed |
description | CXC chemokine receptor 7 (CXCR7) is a G-protein-coupled receptor that signals through the β-arrestin pathway. Its ligands include interferon-inducible T cell α chemoattractant (CXCL11) and stromal cell-derived factor-1 (CXCL12). It interacts with CXCR4, and the two are associated with various cancers, as well as other disease states such as coronary artery disease, stroke, inflammation and human immunodeficiency virus (HIV). Antibodies and small interfering RNA (siRNA) have shown the utility of antagonists of CXCR7 in these disease states. Although some small molecules were initially reported as antagonists due to their displayed activity, many function as agonists while still producing the desired pharmacologic effects. A potential reason for this contradiction is that effects may be due to elevated extracellular CXCL12 levels. |
format | Online Article Text |
id | pubmed-7169404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71694042020-04-20 Advances in CXCR7 Modulators Lounsbury, Nicole Pharmaceuticals (Basel) Review CXC chemokine receptor 7 (CXCR7) is a G-protein-coupled receptor that signals through the β-arrestin pathway. Its ligands include interferon-inducible T cell α chemoattractant (CXCL11) and stromal cell-derived factor-1 (CXCL12). It interacts with CXCR4, and the two are associated with various cancers, as well as other disease states such as coronary artery disease, stroke, inflammation and human immunodeficiency virus (HIV). Antibodies and small interfering RNA (siRNA) have shown the utility of antagonists of CXCR7 in these disease states. Although some small molecules were initially reported as antagonists due to their displayed activity, many function as agonists while still producing the desired pharmacologic effects. A potential reason for this contradiction is that effects may be due to elevated extracellular CXCL12 levels. MDPI 2020-02-21 /pmc/articles/PMC7169404/ /pubmed/32098047 http://dx.doi.org/10.3390/ph13020033 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lounsbury, Nicole Advances in CXCR7 Modulators |
title | Advances in CXCR7 Modulators |
title_full | Advances in CXCR7 Modulators |
title_fullStr | Advances in CXCR7 Modulators |
title_full_unstemmed | Advances in CXCR7 Modulators |
title_short | Advances in CXCR7 Modulators |
title_sort | advances in cxcr7 modulators |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169404/ https://www.ncbi.nlm.nih.gov/pubmed/32098047 http://dx.doi.org/10.3390/ph13020033 |
work_keys_str_mv | AT lounsburynicole advancesincxcr7modulators |